![Alex Shlyankevich](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alex Shlyankevich
Director/Board Member at Vision Technologies Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Frid | M | 52 |
Felicitex Therapeutics, Inc.
![]() Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 years |
Stanislav Karpenko | M | - |
Vision Technologies Ltd.
![]() Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | 10 years |
Maria Vilenchik | M | 55 |
Felicitex Therapeutics, Inc.
![]() Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 years |
Arthur T. Healey | M | 63 |
Felicitex Therapeutics, Inc.
![]() Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 3 years |
Douglas H. Altschuler | M | - |
NupulseCV, Inc.
![]() NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Yuriy Gankin | M | 58 |
Felicitex Therapeutics, Inc.
![]() Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 years |
Piotr Imielski | M | - |
Vision Technologies Ltd.
![]() Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | 10 years |
Elodie Draperi | F | - |
Vision Technologies Ltd.
![]() Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | 10 years |
Richard Sherman | M | - |
NupulseCV, Inc.
![]() NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Kip Kokinakis | M | - |
Vision Technologies Ltd.
![]() Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | - |
Greg Scott | M | - |
NupulseCV, Inc.
![]() NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Brian Novack | M | - |
NupulseCV, Inc.
![]() NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Douglas Moore | M | 67 |
Felicitex Therapeutics, Inc.
![]() Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 2 years |
Dirk Simmons | M | - |
NupulseCV, Inc.
![]() NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Sonna Patel-Raman | F | - |
NupulseCV, Inc.
![]() NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Robert Marc Clement | M | 71 |
Vision Technologies Ltd.
![]() Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | - |
Marc Duey | M | 68 |
Felicitex Therapeutics, Inc.
![]() Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 10 years |
Soulaiman Itani | M | - |
Vision Technologies Ltd.
![]() Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | - |
Thomas Hughes | M | 64 |
Constant Therapeutics LLC
| 1 years |
Michael Kody | M | - |
Felicitex Therapeutics, Inc.
![]() Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Valeria Povolotsky | M | - |
Felicitex Therapeutics, Inc.
![]() Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 15 | 71.43% |
United Kingdom | 6 | 28.57% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alex Shlyankevich
- Personal Network